TrailBio^® Y-27632 Dihydrochloride

ROCK inhibition is commonly used to help reduce anoikis (detachment-induced apoptosis) during the critical recovery period after thawing or enzymatic dissociation into single cells. In human pluripotent stem cell workflows, TrailBio^® Y‑27632 is typically added for the first 24 hours after thawing or single-cell passaging to improve attachment, survival, and recovery.

TrailBio^® Y-27632 can significantly improve hPSC recovery after fluorescence-activated cell sorting, a process that can stress dissociated cells and reduce post-sort viability.

TrailBio^® Endothelial Cells: Used during the initial thawing and subsequent passaging steps of endothelial cells to improve survival and proliferation.

TrailBio^® Vascular Leptomeningeal Cells (VLMCs): Recommended for use during the initial plating of TrailBio^® VLMCs to promote attachment and the formation of a confluent, functional barrier model.

TrailBio^® Y-27632 can cause a transient spindle-like morphology in iPSC colonies. This is a normal pharmacological effect on the cytoskeleton and will resolve once the medium is changed to one without the inhibitor.

While TrailBio^® Y-27632 is excellent for adherent cells, some research suggests it may negatively affect the expansion of CD34+ hematopoietic progenitor cells (HPCs) in suspension cultures. We recommend titration and careful monitoring when using TrailBio^® Y-27632 with TrailBio® HPCs.

TrailBio^® Y-27632 is commonly used in hPSC culture at 10 µM to support survival after thawing, single-cell passaging, or other stressful handling steps. Optimal concentration and exposure time should be determined for each workflow.